182:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
4. M-PHASE-SPECIFIC AGENTS:@0.084848:0.079411:0.417400:0.079411:0.417400:0.059814:0.084848:0.059814:0.013170:0.006585:0.006585:0.021167:0.009878:0.013170:0.015993:0.017404:0.012230:0.012230:0.009878:0.012230:0.013170:0.012230:0.018344:0.006585:0.011289:0.006585:0.018344:0.006585:0.017404:0.019756:0.012230:0.017404:0.009878:0.012230
The completion of the G -phase is marked :@0.084848:0.097387:0.481098:0.097387:0.481098:0.081631:0.084848:0.081631:0.008197:0.011738:0.012508:0.004774:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.006523:0.003848:0.012604:0.011738:0.004782:0.012604:0.006042:0.004776:0.006523:0.011738:0.012508:0.004776:0.016779:0.008285:0.006388:0.013123:0.011738:0.013143:0.007466:0.012508:0.004791:0.003848:0.007466:0.004791:0.018049:0.013143:0.005792:0.009660:0.012508:0.013181:0.005330
2:@0.309884:0.101143:0.318170:0.101143:0.318170:0.088895:0.309884:0.088895:0.008287
by the beginning of the M-phase or mito-:@0.084840:0.113077:0.475749:0.113077:0.475749:0.097321:0.084840:0.097321:0.013123:0.010314:0.006427:0.006523:0.011738:0.012508:0.006427:0.013123:0.012508:0.012950:0.003848:0.011738:0.011738:0.003848:0.011738:0.012950:0.006427:0.012604:0.006042:0.006427:0.006523:0.011738:0.012508:0.006427:0.017684:0.006388:0.013123:0.011738:0.013143:0.007466:0.012508:0.006427:0.012604:0.005792:0.006427:0.018049:0.003848:0.006523:0.012604:0.006388
sis.  Mitosis is further subdivided into  pro-:@0.084840:0.128753:0.475746:0.128754:0.475746:0.112998:0.084840:0.112998:0.007466:0.003848:0.007466:0.005330:0.012451:0.006889:0.017684:0.003848:0.006523:0.012604:0.007466:0.003848:0.007466:0.006902:0.003848:0.007466:0.006902:0.006042:0.011699:0.005792:0.006523:0.011738:0.012508:0.005792:0.006879:0.007466:0.011699:0.013123:0.013181:0.003848:0.010660:0.003848:0.013181:0.012525:0.013181:0.006889:0.003848:0.011738:0.006523:0.012604:0.006889:0.006889:0.013123:0.005715:0.012604:0.820826
27:@0.108967:0.123135:0.121397:0.123135:0.121397:0.113949:0.108967:0.113949:0.006215:0.006215
phase,  metaphase,  anaphase  and  telo-:@0.084841:0.144443:0.475748:0.144443:0.475748:0.128687:0.084841:0.128687:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.005330:0.004204:0.018049:0.012508:0.006523:0.013143:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.005330:0.004204:0.013143:0.011738:0.013143:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.004203:0.013143:0.011738:0.013181:0.005330:0.004204:0.006523:0.012508:0.003848:0.012604:0.006388
phase.  During the prophase-phase, the :@0.084841:0.160120:0.481092:0.160120:0.481092:0.144364:0.084841:0.144364:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.012443:0.008544:0.014316:0.011699:0.005792:0.003848:0.011738:0.012950:0.008544:0.006523:0.011738:0.012508:0.008544:0.013123:0.005715:0.012604:0.013123:0.011738:0.013143:0.007466:0.012508:0.006388:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.008544:0.006523:0.011738:0.012508:0.768798
27:@0.148157:0.154501:0.160587:0.154501:0.160587:0.145315:0.148157:0.145315:0.006215:0.006215
chromosomes  are condensed  and  at-:@0.084853:0.175810:0.475783:0.175810:0.475783:0.160054:0.084853:0.160054:0.012450:0.011738:0.005709:0.012604:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.007466:0.005330:0.006027:0.013143:0.005715:0.012508:0.011372:0.012450:0.012604:0.011738:0.013181:0.012508:0.011738:0.007466:0.012508:0.013181:0.005330:0.006027:0.013143:0.011738:0.013181:0.011372:0.011372:0.013143:0.006523:0.006388
tached to the microtubules, to be segre-:@0.084853:0.191500:0.475782:0.191500:0.475782:0.175744:0.084853:0.175744:0.006523:0.013143:0.012450:0.011738:0.012508:0.013181:0.007389:0.006523:0.012604:0.007389:0.006523:0.011738:0.012508:0.007389:0.018049:0.003848:0.012450:0.005717:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.007466:0.005330:0.007389:0.006523:0.012604:0.007389:0.013123:0.012508:0.007389:0.007466:0.012508:0.012950:0.005713:0.012508:0.006388
gated by the mitotic spindle at the com-:@0.084853:0.207176:0.475758:0.207176:0.475758:0.191420:0.084853:0.191420:0.012950:0.013143:0.006523:0.012508:0.013181:0.006985:0.013123:0.010314:0.006985:0.006523:0.011738:0.012508:0.006985:0.018049:0.003848:0.006523:0.012604:0.006523:0.003848:0.012450:0.006985:0.007466:0.013123:0.003848:0.011738:0.013181:0.003848:0.012508:0.007000:0.013143:0.006523:0.006985:0.006523:0.011738:0.012508:0.006985:0.012450:0.012604:0.018049:0.006388
pletion of mitosis.  Prophase is followed by :@0.084853:0.222866:0.481098:0.222853:0.481098:0.207097:0.084853:0.207110:0.013123:0.003848:0.012508:0.006523:0.003848:0.012604:0.011738:0.004570:0.012604:0.006042:0.004568:0.018049:0.003848:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.012435:0.004580:0.011392:0.005709:0.012604:0.013123:0.011738:0.013143:0.007466:0.012508:0.004570:0.003848:0.007466:0.004580:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.012508:0.013181:0.004580:0.013123:0.010314:0.677543
27:@0.241965:0.217234:0.254395:0.217234:0.254395:0.208049:0.241965:0.208049:0.006215:0.006215
the alignment of the chromosomes in met-:@0.084855:0.238543:0.475768:0.238543:0.475768:0.222787:0.084855:0.222787:0.006523:0.011738:0.012508:0.004349:0.013143:0.003848:0.003848:0.012950:0.011738:0.018049:0.012508:0.011738:0.006523:0.004349:0.012604:0.006042:0.004349:0.006523:0.011738:0.012508:0.004349:0.012450:0.011738:0.005709:0.012604:0.018049:0.012604:0.007466:0.012594:0.018049:0.012508:0.007466:0.004349:0.003848:0.011738:0.004349:0.018049:0.012508:0.006523:0.006388
aphase.  Once aligned, a group of chro-:@0.084855:0.254220:0.475791:0.254220:0.475791:0.238464:0.084855:0.238464:0.013143:0.013123:0.011738:0.013143:0.007466:0.012508:0.005330:0.012431:0.005888:0.016722:0.011738:0.012450:0.012508:0.005888:0.013143:0.003848:0.003848:0.012950:0.011738:0.012508:0.013181:0.005330:0.005888:0.013143:0.005888:0.012950:0.005709:0.012604:0.011699:0.013123:0.005888:0.012604:0.006042:0.005888:0.012450:0.011738:0.005709:0.012604:0.638285
27:@0.161301:0.248601:0.173731:0.248601:0.173731:0.239415:0.161301:0.239415:0.006215:0.006215
mosomes moves towards a pole of the :@0.084855:0.269910:0.481089:0.269910:0.481089:0.254154:0.084855:0.254154:0.018049:0.012604:0.007466:0.012604:0.018049:0.012508:0.007466:0.010275:0.018049:0.012604:0.010660:0.012508:0.007466:0.010275:0.006523:0.012604:0.015990:0.013143:0.005671:0.013181:0.007466:0.010275:0.013143:0.010275:0.013123:0.012604:0.003848:0.012508:0.010275:0.012604:0.006042:0.010275:0.006523:0.011738:0.012508:0.005330
cell in anaphase and the  events of  the :@0.084855:0.285586:0.481125:0.285586:0.481125:0.269830:0.084855:0.269830:0.012450:0.012508:0.003848:0.003848:0.009583:0.003848:0.011738:0.009583:0.013143:0.011738:0.013143:0.013123:0.011738:0.013143:0.007466:0.012508:0.009583:0.013143:0.011738:0.013181:0.009583:0.006523:0.011738:0.012508:0.005330:0.004237:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.009583:0.012604:0.006042:0.005330:0.004241:0.006523:0.011738:0.012508:0.005330
prophase are reversed in telophase as :@0.084855:0.301276:0.481091:0.301276:0.481091:0.285520:0.084855:0.285520:0.013123:0.005715:0.012604:0.013123:0.011738:0.013143:0.007466:0.012508:0.012027:0.013143:0.005715:0.012508:0.012027:0.005711:0.012508:0.010660:0.012508:0.005792:0.007466:0.012508:0.013181:0.012027:0.003848:0.011738:0.012027:0.006523:0.012508:0.003848:0.012604:0.013123:0.011738:0.013143:0.007466:0.012508:0.012027:0.013143:0.007466:0.005330
two nuclei form and the cell divides into :@0.084855:0.316953:0.481081:0.316953:0.481081:0.301197:0.084855:0.301197:0.006523:0.015990:0.012604:0.007966:0.011738:0.011699:0.012450:0.003848:0.012508:0.003848:0.007966:0.006042:0.012604:0.006317:0.018049:0.007966:0.013143:0.011738:0.013181:0.007966:0.006523:0.011738:0.012508:0.007966:0.012450:0.012508:0.003848:0.003848:0.007966:0.013181:0.003848:0.010660:0.003848:0.013181:0.012508:0.007466:0.007986:0.003848:0.011738:0.006523:0.012604:0.005330
two identical daughter cells.:@0.084855:0.332642:0.350035:0.332642:0.350035:0.316886:0.084855:0.316886:0.006523:0.015990:0.012604:0.005330:0.003848:0.013181:0.012508:0.011738:0.006523:0.003848:0.012450:0.013143:0.003848:0.005330:0.013181:0.013143:0.011699:0.012950:0.011738:0.006523:0.012508:0.005792:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
27:@0.350014:0.327017:0.362444:0.327017:0.362444:0.317832:0.350014:0.317832:0.006215:0.006215
The M-phase-specific agents are mainly :@0.103030:0.348320:0.481068:0.348320:0.481068:0.332564:0.103030:0.332564:0.008197:0.011738:0.012508:0.005990:0.017684:0.006388:0.013123:0.011738:0.013143:0.007466:0.012508:0.006388:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005996:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005996:0.013143:0.005713:0.012508:0.005998:0.018049:0.013143:0.003848:0.011738:0.003848:0.010314:0.005330
antitubulin agents as they interfere with :@0.084846:0.364009:0.481109:0.364009:0.481109:0.348253:0.084846:0.348253:0.013143:0.011738:0.006523:0.003848:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.010198:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.010198:0.013143:0.007466:0.010198:0.006523:0.011738:0.012508:0.010314:0.010198:0.003848:0.011738:0.006523:0.012508:0.006704:0.006042:0.012508:0.005711:0.012508:0.010198:0.015990:0.003848:0.006523:0.011738:0.005330
the normal microtubule dynamics, such as :@0.084846:0.379699:0.481080:0.379699:0.481080:0.363943:0.084846:0.363943:0.006523:0.011738:0.012508:0.004570:0.011738:0.012604:0.006317:0.018049:0.013143:0.003848:0.004580:0.018049:0.003848:0.012450:0.005713:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.004580:0.013181:0.010314:0.011738:0.013143:0.018049:0.003848:0.012450:0.007466:0.005330:0.004580:0.007466:0.011699:0.012450:0.011738:0.004580:0.013143:0.007466:0.005330
spindle formation and disassembly, block-:@0.084846:0.395376:0.475746:0.395376:0.475746:0.379620:0.084846:0.379620:0.007466:0.013123:0.003848:0.011738:0.013181:0.003848:0.012508:0.005615:0.006042:0.012604:0.006317:0.018049:0.013143:0.006523:0.003848:0.012604:0.011738:0.005600:0.013143:0.011738:0.013181:0.005600:0.013181:0.003848:0.007466:0.013143:0.007466:0.007466:0.012523:0.018049:0.013123:0.003848:0.010314:0.005330:0.005611:0.013123:0.003848:0.012604:0.012450:0.009660:0.006388
ing the division of  the  nucleus into  two :@0.084846:0.411065:0.481124:0.411065:0.481124:0.395310:0.084846:0.395310:0.003848:0.011738:0.012950:0.010545:0.006523:0.011738:0.012508:0.010545:0.013181:0.003848:0.010660:0.003848:0.007466:0.003848:0.012604:0.011751:0.010545:0.012604:0.006042:0.005330:0.005203:0.006523:0.011738:0.012508:0.005330:0.005203:0.011738:0.011699:0.012450:0.003848:0.012508:0.011699:0.007466:0.010545:0.003848:0.011738:0.006523:0.012604:0.005330:0.005205:0.006523:0.015990:0.012604:0.005330
daughter cells.:@0.084846:0.426742:0.223161:0.426742:0.223161:0.410986:0.084846:0.410986:0.013181:0.013143:0.011699:0.012950:0.011738:0.006523:0.012508:0.005792:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330
25:@0.223153:0.421117:0.235583:0.421117:0.235583:0.411931:0.223153:0.411931:0.006215:0.006215
VINCA ALKALOIDS:@0.084848:0.459161:0.273851:0.459161:0.273851:0.441345:0.084848:0.441345:0.014966:0.005987:0.015822:0.016677:0.015822:0.005987:0.015822:0.009407:0.013256:0.015822:0.009407:0.017960:0.005987:0.014966:0.011118
Vincristine and vinblastine are vinca alka-:@0.084848:0.475990:0.475758:0.475990:0.475758:0.460234:0.084848:0.460234:0.013604:0.003848:0.011738:0.012450:0.005792:0.003848:0.007466:0.006523:0.003848:0.011738:0.012508:0.006331:0.013143:0.011738:0.013181:0.006331:0.010660:0.003848:0.011738:0.013123:0.003848:0.013143:0.007466:0.006523:0.003848:0.011738:0.012508:0.006331:0.013143:0.005715:0.012508:0.006331:0.010660:0.003848:0.011738:0.012450:0.013143:0.006331:0.013143:0.003848:0.009660:0.013143:0.006388
loids, derived  from  the  periwinkle plant :@0.084848:0.491680:0.481098:0.491680:0.481098:0.475924:0.084848:0.475924:0.003848:0.012604:0.003848:0.013181:0.007466:0.005330:0.011719:0.013181:0.012508:0.005792:0.003848:0.010660:0.012508:0.013181:0.005330:0.006379:0.006042:0.005711:0.012604:0.018049:0.005330:0.006373:0.006523:0.011738:0.012508:0.005330:0.006369:0.013123:0.012508:0.005792:0.003848:0.015990:0.003848:0.011738:0.009660:0.003848:0.012508:0.011719:0.013123:0.003848:0.013143:0.011738:0.006523:0.005330
Vinca rosea:@0.084848:0.507370:0.196906:0.507370:0.196906:0.491614:0.084848:0.491614:0.013508:0.003848:0.011738:0.012450:0.013143:0.005869:0.005792:0.012594:0.007466:0.012508:0.013143
, whereas vinorelbine and the :@0.196906:0.507370:0.481071:0.507370:0.481071:0.491614:0.196906:0.491614:0.005330:0.005869:0.015990:0.011738:0.012508:0.005709:0.012508:0.013143:0.007466:0.005869:0.010660:0.003848:0.011738:0.012604:0.005713:0.012508:0.003848:0.013123:0.003848:0.011738:0.012508:0.005869:0.013143:0.011738:0.013181:0.005869:0.006523:0.011738:0.012508:0.005330
newer agent vinflunine are semi-synthetic :@0.084848:0.523047:0.481078:0.523047:0.481078:0.507291:0.084848:0.507291:0.011738:0.012508:0.015990:0.012508:0.005792:0.006412:0.013143:0.012950:0.012508:0.011738:0.006523:0.006413:0.010660:0.003848:0.011738:0.004666:0.004666:0.011699:0.011738:0.003848:0.011738:0.012508:0.006415:0.013143:0.005715:0.012508:0.006419:0.007466:0.012508:0.018049:0.003848:0.006388:0.007466:0.010314:0.011738:0.006523:0.011738:0.012508:0.006523:0.003848:0.012450:0.005330
analogues.  These agents bind tubulin. :@0.084848:0.538736:0.481076:0.538724:0.481076:0.522968:0.084848:0.522980:0.013143:0.011738:0.013143:0.003848:0.012604:0.012950:0.011699:0.012508:0.007466:0.005330:0.015535:0.011122:0.008197:0.011738:0.012508:0.007466:0.012508:0.011122:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.011122:0.013123:0.003848:0.011738:0.013181:0.011122:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.005330:0.218119
1,4:@0.189272:0.533105:0.204810:0.533105:0.204810:0.523919:0.189272:0.523919:0.006215:0.003107:0.006215
Tubulin:@0.084855:0.554413:0.148122:0.554413:0.148122:0.538657:0.084855:0.538657:0.007310:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738
dimers:@0.177255:0.554413:0.238100:0.554413:0.238100:0.538657:0.177255:0.538657:0.013181:0.003848:0.018049:0.012508:0.005792:0.007466
assemble:@0.267233:0.554413:0.355344:0.554413:0.355344:0.538657:0.267233:0.538657:0.013143:0.007466:0.007466:0.012508:0.018049:0.013123:0.003848:0.012508
to:@0.384488:0.554413:0.403615:0.554413:0.403615:0.538657:0.384488:0.538657:0.006523:0.012604
form:@0.432748:0.554413:0.475763:0.554413:0.475763:0.538657:0.432748:0.538657:0.006042:0.012604:0.006319:0.018049
microtubules.:@0.084855:0.570103:0.209719:0.570103:0.209719:0.554347:0.084855:0.554347:0.018049:0.003848:0.012450:0.005715:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.007466:0.005330
1,27:@0.209708:0.564471:0.231460:0.564471:0.231460:0.555285:0.209708:0.555285:0.006215:0.003107:0.006215:0.006215
 :@0.231465:0.570090:0.236795:0.570090:0.236795:0.554334:0.231465:0.554334:0.005330
By binding tubulin, these agents prevent :@0.103022:0.585780:0.481097:0.585780:0.481097:0.570024:0.103022:0.570024:0.011045:0.010314:0.005061:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.005061:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.005330:0.005061:0.006523:0.011738:0.012508:0.007466:0.012508:0.005061:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005061:0.013123:0.005715:0.012508:0.010660:0.012508:0.011738:0.006523:0.005330
polymerisation of mitotic spindles, thereby :@0.084838:0.601456:0.481078:0.601456:0.481078:0.585700:0.084838:0.585700:0.013123:0.012604:0.003848:0.010314:0.018049:0.012508:0.005792:0.003848:0.007466:0.013143:0.006523:0.003848:0.012604:0.011738:0.005523:0.012604:0.006042:0.005513:0.018049:0.003848:0.006523:0.012604:0.006523:0.003848:0.012450:0.005523:0.007466:0.013123:0.003848:0.011738:0.013181:0.003848:0.012508:0.007466:0.005330:0.005523:0.006523:0.011738:0.012508:0.005705:0.012508:0.013123:0.010314:0.005330
blocking cells in mitosis.  Vinca alkaloids :@0.084838:0.617146:0.481085:0.617140:0.481085:0.601384:0.084838:0.601390:0.013123:0.003848:0.012604:0.012450:0.009660:0.003848:0.011738:0.012950:0.009621:0.012450:0.012508:0.003848:0.003848:0.007466:0.009621:0.003848:0.011738:0.009621:0.018049:0.003848:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.006220:0.009621:0.013606:0.003848:0.011738:0.012450:0.013143:0.009621:0.013143:0.003848:0.009660:0.013143:0.003848:0.012604:0.003848:0.013181:0.007466:0.104050
1:@0.314769:0.611521:0.320984:0.611521:0.320984:0.602335:0.314769:0.602335:0.006215
are  highly vesicant and M-G   phase- :@0.084843:0.632830:0.481083:0.632823:0.481083:0.617067:0.084843:0.617074:0.013143:0.005715:0.012508:0.005330:0.009706:0.011738:0.003848:0.012950:0.011738:0.003848:0.010314:0.015048:0.010660:0.012508:0.007466:0.003848:0.012450:0.013143:0.011738:0.006523:0.015048:0.013143:0.011738:0.013181:0.015048:0.017684:0.006388:0.016779:0.008276:0.005330:0.009708:0.013123:0.011738:0.013143:0.007466:0.012508:0.006388:0.081240
1:@0.388059:0.636579:0.396346:0.636579:0.396346:0.624331:0.388059:0.624331:0.008287
specific.:@0.084853:0.648513:0.161399:0.648513:0.161399:0.632757:0.084853:0.632757:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330
1,2:@0.161395:0.642887:0.176933:0.642887:0.176933:0.633702:0.161395:0.633702:0.006215:0.003107:0.006215
The  use  of  vinca alkaloids is limited by :@0.103030:0.664190:0.481093:0.664190:0.481093:0.648434:0.103030:0.648434:0.008197:0.011738:0.012508:0.005330:0.003346:0.011699:0.007466:0.012508:0.005330:0.003356:0.012604:0.006042:0.005330:0.003350:0.010660:0.003848:0.011738:0.012450:0.013143:0.008698:0.013143:0.003848:0.009660:0.013143:0.003848:0.012604:0.003848:0.013181:0.007466:0.008698:0.003848:0.007466:0.008698:0.003848:0.003848:0.018049:0.003848:0.006523:0.012508:0.013181:0.008698:0.013123:0.010314:0.005330
their  dose-related  side effects  (see Ta-:@0.084846:0.679879:0.475761:0.679879:0.475761:0.664124:0.084846:0.664124:0.006523:0.011738:0.012508:0.003848:0.005792:0.005330:0.007466:0.013181:0.012604:0.007466:0.012508:0.006388:0.005715:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330:0.007470:0.007466:0.003848:0.013181:0.012508:0.012815:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330:0.007472:0.007100:0.007466:0.012508:0.012508:0.012815:0.007197:0.013143:0.006388
ble 5), such as neuropathy and bone-mar-:@0.084846:0.695556:0.475731:0.695556:0.475731:0.679800:0.084846:0.679800:0.013123:0.003848:0.012508:0.005330:0.010660:0.007100:0.005330:0.004426:0.007466:0.011699:0.012450:0.011738:0.004426:0.013143:0.007466:0.004426:0.011738:0.012508:0.011699:0.005709:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.004426:0.013143:0.011738:0.013181:0.004426:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.006388
row suppression for vincristine and vinblas-:@0.084846:0.711246:0.475756:0.711246:0.475756:0.695490:0.084846:0.695490:0.005713:0.012604:0.015990:0.005336:0.007466:0.011699:0.013123:0.013123:0.005715:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005338:0.006042:0.012604:0.005792:0.005330:0.010660:0.003848:0.011738:0.012450:0.005792:0.003848:0.007466:0.006523:0.003848:0.011738:0.012508:0.005349:0.013143:0.011738:0.013181:0.005338:0.010660:0.003848:0.011738:0.013123:0.003848:0.013143:0.007485:0.006388
tine respectively.  :@0.084846:0.726922:0.253144:0.726923:0.253144:0.711167:0.084846:0.711166:0.006523:0.003848:0.011738:0.012508:0.005330:0.005707:0.012508:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330:0.006227:0.172307
1:@0.241597:0.721304:0.247812:0.721304:0.247812:0.712118:0.241597:0.712118:0.006215
In comparison, vinflunine has a more fa-:@0.103034:0.742612:0.475765:0.742612:0.475765:0.726857:0.103034:0.726857:0.004349:0.011738:0.005575:0.012450:0.012604:0.018049:0.013123:0.013143:0.005792:0.003848:0.007466:0.012604:0.011738:0.005330:0.005576:0.010660:0.003848:0.011738:0.004666:0.004666:0.011699:0.011738:0.003848:0.011738:0.012508:0.005573:0.011738:0.013143:0.007466:0.005578:0.013143:0.005578:0.018049:0.012604:0.005709:0.012508:0.005575:0.006042:0.013143:0.006388
vourable side-effect profile as it binds rela-:@0.084850:0.758302:0.475748:0.758302:0.475748:0.742546:0.084850:0.742546:0.010660:0.012604:0.011699:0.005792:0.013143:0.013123:0.003848:0.012508:0.004814:0.007466:0.003848:0.013181:0.012508:0.006388:0.012508:0.006104:0.006042:0.012508:0.012450:0.006523:0.004811:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.012508:0.004809:0.013143:0.007466:0.004816:0.003848:0.006523:0.004816:0.013123:0.003848:0.011738:0.013181:0.007466:0.004822:0.005713:0.012508:0.003848:0.013143:0.006388
tively weakly to tubulin, and therefore has :@0.084850:0.773979:0.481071:0.773979:0.481071:0.758223:0.084850:0.758223:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005767:0.015990:0.012508:0.013143:0.009660:0.003848:0.010314:0.005753:0.006523:0.012604:0.005753:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.005330:0.005753:0.013143:0.011738:0.013181:0.005753:0.006523:0.011738:0.012508:0.005711:0.012508:0.006042:0.012604:0.005705:0.012508:0.005753:0.011738:0.013143:0.007466:0.005330
less ability to cause neurotoxicity.:@0.084850:0.789669:0.393441:0.789669:0.393441:0.773913:0.084850:0.773913:0.003848:0.012508:0.007466:0.007466:0.005330:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.006523:0.012604:0.005330:0.012450:0.013143:0.011699:0.007466:0.012508:0.005330:0.011738:0.012508:0.011699:0.005715:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330
35:@0.393431:0.784037:0.405861:0.784037:0.405861:0.774851:0.393431:0.774851:0.006215:0.006215
A  detailed indication and side-effect :@0.103030:0.805339:0.481093:0.805339:0.481093:0.789583:0.103030:0.789583:0.014239:0.005330:0.006975:0.013181:0.012508:0.006523:0.013143:0.003848:0.003848:0.012508:0.013181:0.012315:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.012315:0.013143:0.011738:0.013181:0.012315:0.007466:0.003848:0.013181:0.012508:0.006388:0.012508:0.006098:0.006042:0.012508:0.012450:0.006523:0.005330
profile of vinca alkaloids follows and Table :@0.084846:0.821029:0.481078:0.821029:0.481078:0.805273:0.084846:0.805273:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.012508:0.005363:0.012604:0.006042:0.005367:0.010660:0.003848:0.011738:0.012450:0.013143:0.005369:0.013143:0.003848:0.009660:0.013143:0.003848:0.012604:0.003848:0.013181:0.007466:0.005384:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.007466:0.005372:0.013143:0.011738:0.013181:0.005369:0.007197:0.013143:0.013123:0.003848:0.012508:0.005330
5 addresses the side effects.:@0.084846:0.836705:0.346154:0.836705:0.346154:0.820949:0.084846:0.820949:0.010660:0.005330:0.013143:0.013181:0.013181:0.005719:0.012508:0.007466:0.007466:0.012508:0.007466:0.005330:0.006523:0.011738:0.012508:0.005330:0.007466:0.003848:0.013181:0.012508:0.005330:0.012508:0.006092:0.006042:0.012508:0.012450:0.006523:0.007466:0.005330
Indications:@0.084848:0.867514:0.196946:0.867514:0.196946:0.850007:0.084848:0.850007:0.004832:0.013042:0.014646:0.004276:0.013833:0.014603:0.007248:0.004276:0.014004:0.013042:0.008296
4,13,35:@0.196950:0.861270:0.238383:0.861270:0.238383:0.851064:0.196950:0.851064:0.006905:0.003453:0.006905:0.006905:0.003453:0.006905:0.006905
Vincristine:@0.084848:0.886872:0.190895:0.886872:0.190895:0.869056:0.084848:0.869056:0.014966:0.005131:0.012828:0.013683:0.006842:0.005131:0.009407:0.006414:0.005131:0.012828:0.013683
n :@0.084848:0.901170:0.098177:0.901170:0.098177:0.892730:0.084848:0.892730:0.009762:0.003566
 :@0.115149:0.901170:0.118715:0.901170:0.118715:0.892730:0.115149:0.892730:0.003566
Acute leukaemia:@0.115151:0.904289:0.276307:0.904289:0.276307:0.888533:0.115151:0.888533:0.014239:0.012450:0.011699:0.006523:0.012508:0.005330:0.003848:0.012508:0.011699:0.009660:0.013143:0.012508:0.018049:0.003848:0.013143
n :@0.084848:0.917441:0.098177:0.917441:0.098177:0.909001:0.084848:0.909001:0.009762:0.003566
 :@0.115149:0.917441:0.118715:0.917441:0.118715:0.909001:0.115149:0.909001:0.003566
Hodgkin’s disease and related :@0.115151:0.920561:0.403416:0.920561:0.403416:0.904805:0.115151:0.904805:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013143:0.011738:0.013181:0.005330:0.005709:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.005330
lymphomas:@0.115151:0.936250:0.223486:0.936250:0.223486:0.920494:0.115151:0.920494:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.007466
Vinblastine:@0.524242:0.079455:0.637986:0.079455:0.637986:0.061640:0.524242:0.061640:0.014966:0.005131:0.012828:0.014111:0.005131:0.014111:0.009407:0.006414:0.005131:0.012828:0.013683
n :@0.524242:0.093736:0.537570:0.093736:0.537570:0.085296:0.524242:0.085296:0.009762:0.003566
 :@0.554542:0.093736:0.558108:0.093736:0.558108:0.085296:0.554542:0.085296:0.003566
Palliative treatment of malignant :@0.554545:0.096855:0.865483:0.096855:0.865483:0.081099:0.554545:0.081099:0.011392:0.013143:0.003848:0.003848:0.003862:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.018049:0.013143:0.003837:0.003848:0.012950:0.011738:0.013143:0.011738:0.006523:0.005330
non-Hodgkin’s lymphoma :@0.554545:0.112518:0.799886:0.112518:0.799886:0.096762:0.554545:0.096762:0.011738:0.012604:0.011738:0.006388:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330
n :@0.524242:0.125655:0.537570:0.125655:0.537570:0.117215:0.524242:0.117215:0.009762:0.003566
 :@0.554542:0.125655:0.558108:0.125655:0.558108:0.117215:0.554542:0.117215:0.003566
Hodgkin’s disease:@0.554545:0.128774:0.721338:0.128774:0.721338:0.113018:0.554545:0.113018:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508
n :@0.524242:0.141908:0.537570:0.141908:0.537570:0.133468:0.524242:0.133468:0.009762:0.003566
 :@0.554542:0.141908:0.558108:0.141908:0.558108:0.133468:0.554542:0.133468:0.003566
Cancer of the testes :@0.554545:0.145028:0.749517:0.145028:0.749517:0.129272:0.554545:0.129272:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.012604:0.006042:0.005330:0.006502:0.011738:0.012508:0.005330:0.006514:0.012508:0.007466:0.006523:0.012508:0.007466:0.005330
n :@0.524242:0.158162:0.537570:0.158162:0.537570:0.149722:0.524242:0.149722:0.009762:0.003566
 :@0.554542:0.158162:0.558108:0.158162:0.558108:0.149722:0.554542:0.149722:0.003566
Chorio- and breast cancer:@0.554545:0.161281:0.803771:0.161281:0.803771:0.145525:0.554545:0.145525:0.015644:0.011738:0.012604:0.005792:0.003848:0.012604:0.006388:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.005713:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792
n :@0.524242:0.174416:0.537570:0.174416:0.537570:0.165975:0.524242:0.165975:0.009762:0.003566
 :@0.554542:0.174416:0.558108:0.174416:0.558108:0.165975:0.554542:0.165975:0.003566
Melanoma:@0.554545:0.177535:0.657261:0.177535:0.657261:0.161779:0.554545:0.161779:0.017684:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143
109:@0.657259:0.171916:0.675904:0.171916:0.675904:0.162730:0.657259:0.162730:0.006215:0.006215:0.006215
Vinorelbine :@0.524242:0.194259:0.648248:0.194259:0.648248:0.176443:0.524242:0.176443:0.014966:0.005131:0.012828:0.013683:0.006842:0.013683:0.005131:0.014111:0.005131:0.012828:0.013683:0.005987
n :@0.524242:0.208540:0.537570:0.208540:0.537570:0.200099:0.524242:0.200099:0.009762:0.003566
 :@0.554542:0.208540:0.558108:0.208540:0.558108:0.200099:0.554542:0.200099:0.003566
Palliative treatment of advanced, :@0.554545:0.211659:0.875837:0.211659:0.875837:0.195903:0.554545:0.195903:0.011392:0.013143:0.003848:0.003848:0.003862:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.013143:0.013181:0.010651:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.005330
inoperable non-small-cell lung cancer :@0.554545:0.227322:0.914282:0.227322:0.914282:0.211566:0.554545:0.211566:0.003848:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
as monotherapy or as combination :@0.554545:0.242985:0.888612:0.242985:0.888612:0.227229:0.554545:0.227229:0.013143:0.007466:0.005330:0.018049:0.012604:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012604:0.005792:0.005330:0.013143:0.007466:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
therapy (more effective):@0.554545:0.258649:0.784549:0.258649:0.784549:0.242893:0.554545:0.242893:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.007100:0.018049:0.012604:0.005703:0.012508:0.005330:0.012508:0.006092:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.007100
n :@0.524242:0.271790:0.537570:0.271790:0.537570:0.263349:0.524242:0.263349:0.009762:0.003566
 :@0.554542:0.271790:0.558108:0.271790:0.558108:0.263349:0.554542:0.263349:0.003566
Metastatic breast cancer in patients in :@0.554545:0.274909:0.918927:0.274909:0.918927:0.259153:0.554545:0.259153:0.017684:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.013123:0.005713:0.012508:0.013143:0.007466:0.006523:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.003839:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.003848:0.011738:0.005330
whom anthracycline first-line :@0.554545:0.290572:0.825632:0.290572:0.825632:0.274816:0.554545:0.274816:0.015990:0.011738:0.012604:0.018049:0.005330:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330
monotherapy has failed or who have :@0.554545:0.306235:0.906354:0.306235:0.906354:0.290480:0.554545:0.290480:0.018049:0.012604:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.011738:0.013143:0.007466:0.005330:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
relapsed within six months of :@0.554545:0.321899:0.823687:0.321899:0.823687:0.306143:0.554545:0.306143:0.005713:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.013181:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330:0.007466:0.003848:0.009236:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.012604:0.006042:0.005330
anthracycline-based adjuvant :@0.554545:0.337562:0.844239:0.337562:0.844239:0.321806:0.554545:0.321806:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330
therapy:@0.554545:0.353225:0.627685:0.353225:0.627685:0.337470:0.554545:0.337470:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.524242:0.366371:0.537570:0.366371:0.537570:0.357931:0.524242:0.357931:0.009762:0.003566
 :@0.554542:0.366371:0.558108:0.366371:0.558108:0.357931:0.554542:0.357931:0.003566
Prostate cancer as palliative :@0.554545:0.369490:0.824935:0.369490:0.824935:0.353734:0.554545:0.353734:0.011392:0.005713:0.012604:0.007466:0.006523:0.013143:0.006523:0.012508:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.013143:0.007466:0.005330:0.013123:0.013143:0.003848:0.003848:0.003848:0.013143:0.006523:0.003848:0.010678:0.012508:0.005330
treatment.:@0.554545:0.385153:0.653099:0.385153:0.653099:0.369398:0.554545:0.369398:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
106:@0.653087:0.379537:0.671732:0.379537:0.671732:0.370351:0.653087:0.370351:0.006215:0.006215:0.006215
   Contra-indications, special precau-:@0.542424:0.400821:0.915165:0.400821:0.915165:0.385065:0.542424:0.385065:0.005330:0.006791:0.000000:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.020820:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003862:0.020820:0.013123:0.005717:0.012508:0.012450:0.013143:0.011699:0.006388
tions and drug interactions: See :@0.554546:0.416485:0.863320:0.416485:0.863320:0.400729:0.554546:0.400729:0.006523:0.003848:0.012604:0.011738:0.007466:0.007870:0.013143:0.011738:0.013181:0.007870:0.013181:0.005792:0.011699:0.012950:0.007870:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.007861:0.009583:0.012508:0.012508:0.005330
MIMS :@0.865860:0.416485:0.920489:0.416485:0.920489:0.400729:0.865860:0.400729:0.017684:0.004349:0.017684:0.009583:0.005330
Monthly, MDR:@0.554546:0.432148:0.684258:0.432148:0.684258:0.416392:0.554546:0.416392:0.017684:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.006252:0.017684:0.014316:0.011680
 or manufacturer’s prod-:@0.684258:0.432148:0.915159:0.432148:0.915159:0.416392:0.684258:0.416392:0.006263:0.012604:0.005792:0.006258:0.018049:0.013143:0.011738:0.011699:0.006042:0.013143:0.012450:0.006523:0.011699:0.005705:0.012508:0.005792:0.006754:0.007466:0.006261:0.013123:0.005715:0.012604:0.013181:0.006388
uct literature.:@0.554546:0.447811:0.677973:0.447811:0.677973:0.432055:0.554546:0.432055:0.011699:0.012450:0.006523:0.005330:0.003848:0.003848:0.006523:0.012508:0.005792:0.013143:0.006523:0.011699:0.005702:0.012508:0.005330
n :@0.524242:0.460952:0.537570:0.460952:0.537570:0.452512:0.524242:0.452512:0.009762:0.003566
 :@0.554542:0.460952:0.558108:0.460952:0.558108:0.452512:0.554542:0.452512:0.003566
Cervical cancer:@0.554545:0.464072:0.705848:0.464072:0.705848:0.448316:0.554545:0.448316:0.015644:0.012508:0.005792:0.010660:0.003848:0.012450:0.013143:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792
99:@0.705844:0.458453:0.718274:0.458453:0.718274:0.449267:0.705844:0.449267:0.006215:0.006215
TAXANES:@0.524242:0.496461:0.617461:0.496461:0.617461:0.478646:0.524242:0.478646:0.008980:0.015822:0.014539:0.015822:0.015822:0.011118:0.011118
Paclitaxel and its related semi-synthetic :@0.524242:0.513273:0.920460:0.513273:0.920460:0.497517:0.524242:0.497517:0.011392:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.011565:0.013143:0.011738:0.013181:0.011565:0.003848:0.006523:0.007466:0.011565:0.005713:0.012508:0.003848:0.013143:0.006523:0.012508:0.013181:0.011565:0.007466:0.012508:0.018049:0.003848:0.006388:0.007466:0.010314:0.011738:0.006523:0.011738:0.012508:0.006523:0.003848:0.012450:0.005330
compounds  docetaxel  and cabazitaxel :@0.524242:0.528937:0.920478:0.528937:0.920478:0.513181:0.524242:0.513181:0.012450:0.012604:0.018049:0.013123:0.012604:0.011699:0.011738:0.013181:0.007466:0.005330:0.006261:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330:0.006261:0.013143:0.011738:0.013181:0.011603:0.012450:0.013143:0.013123:0.013143:0.008178:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.005330
are alkaloid esters derived from the Pacific :@0.524242:0.544600:0.920481:0.544600:0.920481:0.528844:0.524242:0.528844:0.013143:0.005715:0.012508:0.004416:0.013143:0.003848:0.009660:0.013143:0.003848:0.012604:0.003848:0.013181:0.004422:0.012508:0.007466:0.006523:0.012508:0.005792:0.007466:0.004414:0.013181:0.012508:0.005792:0.003848:0.010660:0.012508:0.013181:0.004420:0.006042:0.005711:0.012604:0.018049:0.004418:0.006523:0.011738:0.012508:0.004410:0.011392:0.013143:0.012450:0.003848:0.004686:0.004686:0.012450:0.005330
and European  yew trees  respectively.:@0.524242:0.560263:0.893396:0.560263:0.893396:0.544507:0.524242:0.544507:0.013143:0.011738:0.013181:0.009987:0.010314:0.011699:0.005711:0.012604:0.013123:0.012508:0.013143:0.011738:0.005330:0.004645:0.010314:0.012508:0.015990:0.009987:0.006523:0.005711:0.012508:0.012508:0.007466:0.005330:0.004647:0.005713:0.012508:0.007466:0.013123:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.005330
4,36:@0.893393:0.554651:0.915145:0.554651:0.915145:0.545465:0.893393:0.545465:0.006215:0.003107:0.006215:0.006215
  :@0.915150:0.560270:0.920481:0.560270:0.920481:0.544514:0.915150:0.544514:0.000000:0.005330
Paclitaxel and docetaxel are G -M phase-:@0.524241:0.575933:0.915147:0.575936:0.915147:0.560180:0.524241:0.560177:0.011392:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.004407:0.013143:0.011738:0.013181:0.004407:0.013181:0.012604:0.012450:0.012508:0.006523:0.013143:0.009236:0.012508:0.003848:0.004407:0.013143:0.005715:0.012508:0.004407:0.016779:0.008290:0.006388:0.017684:0.004407:0.013123:0.011738:0.013143:0.007466:0.012508:-0.269021
2:@0.814013:0.579691:0.822300:0.579691:0.822300:0.567444:0.814013:0.567444:0.008287
specific agents, as they bind to tubulin in :@0.524238:0.591599:0.920475:0.591599:0.920475:0.575843:0.524238:0.575843:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.007041:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.007031:0.013143:0.007466:0.007043:0.006523:0.011738:0.012508:0.010314:0.007033:0.013123:0.003848:0.011738:0.013181:0.007041:0.006523:0.012604:0.007031:0.006523:0.011699:0.013123:0.011699:0.003848:0.003848:0.011738:0.007039:0.003848:0.011738:0.005330
the microtubules, causing cell arrest at mi-:@0.524238:0.607262:0.915151:0.607262:0.915151:0.591506:0.524238:0.591506:0.006523:0.011738:0.012508:0.005032:0.018049:0.003848:0.012450:0.005713:0.012604:0.006523:0.011699:0.013123:0.011699:0.003848:0.012508:0.007466:0.005330:0.005042:0.012450:0.013143:0.011699:0.007466:0.003848:0.011738:0.012950:0.005042:0.012450:0.012508:0.003848:0.003848:0.005042:0.013143:0.005792:0.005711:0.012508:0.007466:0.006523:0.005042:0.013143:0.006523:0.005042:0.018049:0.003848:0.006388
tosis, which may lead to apoptosis.:@0.524238:0.622926:0.848434:0.622926:0.848434:0.607170:0.524238:0.607170:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.005330:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330:0.018049:0.013143:0.010314:0.005330:0.003848:0.012508:0.013143:0.013181:0.005330:0.006523:0.012604:0.005330:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330
2,36:@0.848431:0.617313:0.870183:0.617313:0.870183:0.608128:0.848431:0.608128:0.006215:0.003107:0.006215:0.006215
Although paclitaxel was isolated in 1966, :@0.542424:0.638598:0.920454:0.638598:0.920454:0.622842:0.542424:0.622842:0.014239:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.004466:0.013123:0.013143:0.012450:0.003848:0.003848:0.006523:0.013143:0.009236:0.012508:0.003848:0.004495:0.015990:0.013143:0.007466:0.004483:0.003848:0.007466:0.012604:0.003848:0.013143:0.006523:0.012508:0.013181:0.004483:0.003848:0.011738:0.004483:0.010660:0.010660:0.010660:0.010660:0.005330:0.005330
it did not appear in clinical practice until :@0.524239:0.654261:0.920491:0.654261:0.920491:0.638505:0.524239:0.638505:0.003848:0.006523:0.007197:0.013181:0.003848:0.013181:0.007197:0.011738:0.012604:0.006523:0.007197:0.013143:0.013123:0.013123:0.012508:0.013143:0.005792:0.007197:0.003848:0.011738:0.007197:0.012450:0.003848:0.003848:0.011738:0.003848:0.012450:0.013143:0.003848:0.007208:0.013123:0.005792:0.013143:0.012450:0.006523:0.003848:0.012450:0.012508:0.007197:0.011699:0.011738:0.006523:0.003848:0.003848:0.005330
the 1990s.  Today, it is indicated for a vari-:@0.524239:0.669924:0.915163:0.669929:0.915163:0.654173:0.524239:0.654168:0.006523:0.011738:0.012508:0.005105:0.010660:0.010660:0.010660:0.010676:0.007466:0.005330:0.012439:0.005118:0.007254:0.012604:0.013181:0.013143:0.010314:0.005330:0.005118:0.003848:0.006523:0.005118:0.003848:0.007466:0.005118:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005118:0.006042:0.012604:0.005792:0.005103:0.013143:0.005118:0.010660:0.013143:0.005792:0.003848:-0.405753
25:@0.615570:0.664310:0.628000:0.664310:0.628000:0.655124:0.615570:0.655124:0.006215:0.006215
ety of cancers, including metastatic breast :@0.524249:0.685592:0.920479:0.685592:0.920479:0.669836:0.524249:0.669836:0.012506:0.006521:0.010122:0.004965:0.012411:0.005850:0.004965:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.007274:0.005138:0.004965:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012758:0.004965:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.004965:0.012931:0.005521:0.012315:0.012950:0.007274:0.006519:0.005330
cancer after combination therapy failure :@0.524249:0.701256:0.920485:0.701256:0.920485:0.685500:0.524249:0.685500:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.008986:0.012950:0.005850:0.006331:0.012315:0.005600:0.008986:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011545:0.008986:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.008986:0.005850:0.012950:0.003656:0.003656:0.011507:0.005521:0.012506:0.005330
or relapse after six months of adjuvant :@0.524249:0.716919:0.920483:0.716919:0.920483:0.701163:0.524249:0.701163:0.012411:0.005600:0.012508:0.005519:0.012315:0.003656:0.012950:0.012931:0.007274:0.012315:0.012508:0.012950:0.005850:0.006331:0.012315:0.005600:0.012508:0.007274:0.003656:0.009044:0.012508:0.017857:0.012411:0.011545:0.006331:0.011545:0.007274:0.012508:0.012411:0.005850:0.012508:0.012950:0.012989:0.003714:0.011507:0.010468:0.012950:0.011545:0.006521:0.005330
chemotherapy (including anthracyclines), :@0.524249:0.732582:0.920485:0.732582:0.920485:0.716826:0.524249:0.716826:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.008005:0.006908:0.003656:0.011545:0.012257:0.003656:0.011507:0.012989:0.003656:0.011545:0.012758:0.008005:0.012950:0.011545:0.006331:0.011545:0.005600:0.012950:0.012257:0.010122:0.012257:0.003656:0.003656:0.011545:0.012315:0.007274:0.006908:0.005326:0.005330
first-line therapy of advanced or metastat-:@0.524249:0.748246:0.915176:0.748246:0.915176:0.732490:0.524249:0.732490:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.003656:0.003656:0.011545:0.012315:0.005984:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005984:0.012411:0.005850:0.005984:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.005982:0.012411:0.005600:0.005984:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.006388
ic breast cancer in combination with tras-:@0.524249:0.763909:0.915174:0.763909:0.915174:0.748153:0.524249:0.748153:0.003656:0.012257:0.007023:0.012931:0.005519:0.012315:0.012950:0.007274:0.006331:0.007023:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.007023:0.003656:0.011545:0.007023:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011545:0.007023:0.015798:0.003656:0.006331:0.011545:0.007023:0.006331:0.005600:0.012950:0.007274:0.006388
tuzumab in patients who overexpress HER2 :@0.524249:0.779572:0.920508:0.779572:0.920508:0.763816:0.524249:0.763816:0.006331:0.011507:0.007986:0.011507:0.017857:0.012950:0.012931:0.005792:0.003656:0.011545:0.005792:0.012931:0.012950:0.006331:0.003656:0.012315:0.011545:0.006331:0.007274:0.005792:0.015798:0.011545:0.012411:0.005792:0.012411:0.010468:0.012315:0.005521:0.012315:0.009044:0.012931:0.005521:0.012315:0.007274:0.007274:0.005792:0.012950:0.010122:0.011488:0.010664:0.005330
at a 2+ or 3+ level as determined by immu-:@0.524249:0.795236:0.915132:0.795236:0.915132:0.779480:0.524249:0.779480:0.012950:0.006331:0.005042:0.012950:0.005042:0.010468:0.011468:0.005042:0.012411:0.005600:0.005042:0.010468:0.011468:0.005042:0.003656:0.012315:0.010468:0.012315:0.003656:0.005042:0.012950:0.007274:0.005042:0.012989:0.012315:0.006331:0.012315:0.006131:0.017857:0.003656:0.011545:0.012315:0.012989:0.005042:0.012931:0.010122:0.005042:0.003656:0.017857:0.017857:0.011507:0.006388
nohistochemistry,  palliative  treatment  of :@0.524249:0.810899:0.920493:0.810899:0.920493:0.795143:0.524249:0.795143:0.011545:0.012411:0.011545:0.003656:0.007274:0.006331:0.012411:0.012257:0.011545:0.012315:0.017857:0.003656:0.007274:0.006331:0.005600:0.010122:0.005138:0.005330:0.008380:0.012931:0.012950:0.003656:0.003656:0.003656:0.012950:0.006331:0.003656:0.010468:0.012315:0.005330:0.008380:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.005330:0.008380:0.012411:0.006040:0.005330
advanced non-small-cell lung cancer :@0.524249:0.826562:0.920466:0.826562:0.920466:0.810806:0.524249:0.810806:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.020224:0.011545:0.012411:0.011545:0.006196:0.007274:0.017857:0.012950:0.003656:0.003656:0.006196:0.012257:0.012315:0.003656:0.003656:0.020224:0.003656:0.011507:0.011545:0.012758:0.020224:0.012257:0.012950:0.011545:0.012257:0.012315:0.005788:0.005330
when curative surgery and/or radiothera-:@0.524249:0.842226:0.915191:0.842226:0.915191:0.826470:0.524249:0.826470:0.015798:0.011545:0.012315:0.011545:0.008255:0.012257:0.011507:0.005600:0.012950:0.006331:0.003656:0.010468:0.012315:0.008255:0.007274:0.011507:0.005613:0.012758:0.012315:0.005600:0.010122:0.008255:0.012950:0.011545:0.012989:0.008217:0.012411:0.005600:0.008255:0.005600:0.012950:0.012989:0.003656:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.006388
py is not applicable, palliative treatment of :@0.524249:0.857889:0.920483:0.857889:0.920483:0.842133:0.524249:0.842133:0.012931:0.010122:0.004791:0.003656:0.007274:0.004791:0.011545:0.012411:0.006331:0.004791:0.012950:0.012931:0.012931:0.003656:0.003656:0.012257:0.012950:0.012931:0.003656:0.012315:0.005138:0.004791:0.012931:0.012950:0.003656:0.003656:0.003656:0.012950:0.006331:0.003656:0.010468:0.012315:0.004791:0.006331:0.005519:0.012315:0.012950:0.006331:0.017857:0.012315:0.011545:0.006331:0.004791:0.012411:0.006040:0.005330
stage 3 or 4 locally advanced ovarian can-:@0.524249:0.873552:0.915159:0.873552:0.915159:0.857796:0.524249:0.857796:0.007274:0.006331:0.012950:0.012758:0.012315:0.004349:0.010468:0.004349:0.012411:0.005600:0.004349:0.010468:0.004349:0.003656:0.012411:0.012257:0.012950:0.003656:0.003656:0.010122:0.004349:0.012950:0.012989:0.010468:0.012950:0.011545:0.012257:0.012315:0.012989:0.004349:0.012411:0.010468:0.012950:0.005600:0.003656:0.012950:0.011545:0.004349:0.012257:0.012950:0.011545:0.006388
cer after surgical resection in combination :@0.524249:0.889216:0.920497:0.889216:0.920497:0.873460:0.524249:0.873460:0.012257:0.012315:0.005600:0.006292:0.012950:0.005850:0.006331:0.012315:0.005600:0.006292:0.007274:0.011507:0.005613:0.012758:0.003656:0.012257:0.012950:0.003656:0.006292:0.005521:0.012315:0.007274:0.012315:0.012257:0.006331:0.003656:0.012411:0.011545:0.006292:0.003656:0.011545:0.006292:0.012257:0.012411:0.017857:0.012931:0.003656:0.011545:0.012950:0.006331:0.003656:0.012411:0.011734:0.005330
with cisplatin, and palliative management :@0.524249:0.904879:0.920448:0.904879:0.920448:0.889123:0.524249:0.889123:0.015798:0.003656:0.006331:0.011545:0.006369:0.012257:0.003656:0.007274:0.012931:0.003656:0.012950:0.006331:0.003656:0.011545:0.005138:0.006369:0.012950:0.011545:0.012989:0.006369:0.012931:0.012950:0.003656:0.003656:0.003656:0.012950:0.006331:0.003656:0.010468:0.012315:0.006369:0.017857:0.012950:0.011545:0.012950:0.012758:0.012315:0.017857:0.012315:0.011545:0.006521:0.005330
of metastatic ovarian cancer after failure :@0.524249:0.920542:0.920514:0.920542:0.920514:0.904786:0.524249:0.904786:0.012411:0.005850:0.007851:0.017857:0.012315:0.006331:0.012950:0.007274:0.006331:0.012950:0.006331:0.003656:0.012257:0.007841:0.012411:0.010468:0.012950:0.005600:0.003656:0.012950:0.011545:0.007851:0.012257:0.012950:0.011545:0.012257:0.012315:0.005600:0.007841:0.012950:0.005850:0.006331:0.012315:0.005600:0.007841:0.005850:0.012950:0.003656:0.003656:0.011507:0.005521:0.012506:0.005330
of  first-line  or  subsequent  chemotherapy, :@0.524249:0.936206:0.920520:0.936206:0.920520:0.920450:0.524249:0.920450:0.012411:0.005850:0.005330:0.004541:0.004589:0.004589:0.005600:0.007274:0.006331:0.006196:0.003656:0.003656:0.011545:0.012315:0.005330:0.004541:0.012411:0.005600:0.005330:0.004539:0.007274:0.011507:0.012931:0.007274:0.012315:0.012931:0.011507:0.012315:0.011545:0.006331:0.005330:0.004539:0.012257:0.011545:0.012315:0.017857:0.012411:0.006331:0.011545:0.012315:0.005600:0.012950:0.012931:0.010122:0.005326:0.005330
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578